Adcytherix
Adcytherix is a biopharmaceutical company developing novel antibody-drug conjugates (ADCs), like its lead candidate ADCX-020, for cancer treatment.
Secondary Market Price
How Adcytherix Measures Up
To help you manage your Adcytherix equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Adcytherix's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Adcytherix Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Adcytherix's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Adcytherix is a biotechnology research company developing novel antibody-drug conjugates (ADCs) for diseases with high unmet needs, primarily cancer. The company is currently preparing to enter the clinic with its lead candidate, ADCX-020, utilizing its operational ADCX-Engine to design next-generation ADCs. Adcytherix was founded in 2024 by Jack Elands, Pontifax Venture Capital, Xavier Preville, and Carsten Dehning. Within 20 months of its founding, the company advanced its lead program to the point of filing an Investigational New Drug (IND) application.
The company plans to advance ADCX-020 into clinical trials and expand its pipeline of proprietary ADCs that leverage novel payload classes to address treatment-resistant cancers. A significant recent announcement was the FDA's clearance of the IND for ADCX-020, enabling the start of its first-in-human clinical study. This follows the company's €105 million Series A funding round, which closed in November 2025 and was the largest ADC-focused Series A in Europe for that year. The funding is intended to move ADCX-020 into the clinic and expand the company's pipeline.
- Bpifrance
- Kurma Partners
- Andera Partners
- Angelini Ventures
- Surveyor Capital
- aMoon
- Pontifax
- DawnBiopharma
- Pureos Bioventures
- RA Capital
- Co-Founder, Jack Elands
- Co-Founder, Xavier Preville
- Co-Founder, Carsten Dehning
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Adcytherix worth joining?
Deciding if a startup is worth joining depends on its growth prospects and your personal financial goals. Prospect can help you evaluate the potential value of your equity compensation by using proprietary models to forecast the company's future.
What should I do with my Adcytherix stock?
Managing private company stock involves complex decisions about when to exercise options and sell shares to maximize value and minimize taxes. Prospect provides personalized, multi-year strategies to help you make the most of your equity holdings.
Can you sell Adcytherix stock?
As a private company, selling Adcytherix stock is typically limited to specific events like tender offers or secondary market sales. Prospect offers tools to help you decide how much to sell and which shares are the most tax-optimal to offload during these liquidity events.
How can I find the value of my Adcytherix stock?
The current value is based on the company's latest valuation, but the future value is what determines your potential earnings. Prospect uses predictive models trained on investor-grade data to help you forecast the future value of your shares and understand your potential net equity.
What is Adcytherix's equity worth?
The worth of private equity is not a single number but a range of potential outcomes based on the company's future success. Prospect can help you model different scenarios and project your equity's value based on data from funding rounds, market trends, and more.
What is Adcytherix's stock ticker symbol?
As a private company, Adcytherix is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company goes public through an IPO.
Can I buy or sell Adcytherix stock?
Buying Adcytherix stock is generally restricted to exercising your employee stock options, while selling is limited to liquidity events like tender offers. Prospect specializes in helping you create tax-optimized strategies for both exercising your options and selling your shares.
What is the criteria to buy or invest in Adcytherix stock?
Investing in a private company like Adcytherix is typically reserved for employees receiving equity compensation or accredited investors participating in funding rounds. If you are an employee, Prospect can help you manage your equity and make informed decisions about your holdings.
